APOBEC3G antibody (C-Term)

Catalog No. ABIN374818

Product Details anti-APOBEC3G Antibody

Target: APOBEC3G (Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3G (APOBEC3G))

Binding Specificity: C-Term

Reactivity: Human

Host: Goat

Clonality: Polyclonal

Conjugate: This APOBEC3G antibody is un-conjugated

Application: Western Blotting (WB)

Specificity: This antibody reacts to APOBEC3G.

Purification: Affinity chromatography

Immunogen: Peptide with sequence C-DEHSQDLSGRLR, from the C Terminus of the protein sequence

Application Details

Application Notes: Peptide ELISA: 1/16000. Western Blot: 0.5 - 1.5 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 0,5 mg/mL

Buffer: Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for APOBEC3G

Target: APOBEC3G (Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3G (APOBEC3G))

Alternative Name: APOBEC3G (APOBEC3G Products)

Synonyms: A3G antibody, ARCD antibody, ARP-9 antibody, ARP9 antibody, CEM-15 antibody, CEM15 antibody, bK150C2.7 antibody, dJ494G10.1 antibody, apolipoprotein B mRNA editing enzyme catalytic subunit 3G antibody, APOBEC3G antibody

Background: APOBEC3G is a DNA deaminase (cytidine deaminase) that mediates a form of innate resistance to retroviral infections (at least to HIV1 infection) by triggering G-to-A hypermutation in the newly synthetized viral DNA. The replacements C-to-U in the minus strand DNA of HIV1 during reverse transcription, leads to G-to-A transitions in the plus strand. The inhibition of viral replication is either due to the degradation of the minus strand before its integration or to the lethality of the hypermutations. Modification of both DNA strands is not excluded. This antiviral activity is neutralized by the virion infectivity factor (VIF), that prevents the incorporation of APOBEC3G into progeny HIV1 virions by both inhibiting its translation and/or by inducing its ubiquitination and subsequent degradation by the 26S proteasome. APOBEC3G binds a variety of RNAs, but does not display detectable APOB, NF1 and NAT1 mRNA editing. APOBEC3G is involved in hepatitis B virus (HBV) resistance probably primarily by inhibiting viral pregenomic RNA packaging. This activity is independent of the cytidine deaminase activity, as the inactivated protein is able to inhibit HBV replication. During HBV infection, APOBEC3G does not seem to be involved in the editing of HBV DNA, but this might occur in particular cellular contexts or with specific viral strains. APOBEC3G is a homodimer. It interacts with APOBEC3B, APOBEC3F and HIV1 VIF in a species specific manner. It is expressed in spleen, testes, ovary and peripheral blood leukocytes and CD4+ lymphocytes. Also expressed in non permissive peripheral blood mononuclear cells, and several tumor cell lines, no expression detected in permissive lymphoid and non-lymphoid cell lines. Normally not expressed in the liver, but it is possible that it is induced in the course of HBV infection, for instance under the influence of cytokines. APOBEC3G is ubiquitinated in the presence of HIV1 VIF. Association with VIF targets the protein for proteolysis by the ubiquitin dependent proteasome pathway. APOBEC3G inhibits also the infectivity of retroviral particles only distantly related to HIV1, such as the simian immunodeficiency virus (SIV), the equine infectious anemia virus (EIAV) and the murine leukemia virus (MLV).Synonyms: APOBEC-3G, APOBEC-related cytidine deaminase, ARCD, ARP9, CEM15, DNA dC->dU-editing enzyme APOBEC-3G, MDS019

Gene ID: 60489, 9606

UniProt: Q9HC16